Strontium-89 for prostate cancer with bone metastases: The potential of cancer control and improvement of overall survival

Annals of Nuclear Medicine

Volumn 28, Issue 1, 2014, Pages 11-16

  Kuroda, Isao ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone metastasis; Prostate cancer; PSA; Strontium 89; Survival

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CARBOXYTERMINAL TELOPEPTIDE OF TYPE I COLLAGEN; COLLAGEN; DOCETAXEL; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89; UNCLASSIFIED DRUG;

ADULT; AGED; ANALGESIA; ARTICLE; BONE METASTASIS; CANCER CONTROL; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GLEASON SCORE; HUMAN; MALE; MEDICAL HISTORY; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SPINAL PAIN; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PAIN MANAGEMENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; STRONTIUM RADIOISOTOPES; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84893157077     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-013-0775-8     Document Type: Article

References (14)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Namiki M, Akaza H, Lee SE, Song JM, Umbas R, Zhou L, et al. Prostate Cancer Working Group report. Jpn J Clin Oncol. 2010;40(Suppl 1):i70-5.
3. Nakata S, Ohtake N, Yamanaka H. Epidemiology of prostate cancer in Japan. Nihon Rinsyo. 2011;69(Suppl 5):181-6 (in Japanese).
4. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46:517-25.
5. Blake GM, Zivanovic MA, Blaquiere RM, Fine DR, McEwan AJ, Ackery DM. Strontium-89 therapy: measurement of absorbed dose to skeletal metastases. J Nucl Med. 1988;29:549-57.
6. Zyskowski A, Lamb D, Morum P, Hamilton D, Johnson C. Strontium-89 treatment for prostate cancer bone metastases: does a prostate-specific antigen response predict for improved survival? Australas Radiol. 2001;45:39-42.
7. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer. 2010;46:517-25.
8. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-54.
9. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187-97.
10. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-13.
11. Turner SL, Gruenewald S, Spry N, Gebski V, Metastron Users Group. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer. Br J Cancer. 2001;84:297-302.
12. Yoshimura M, Saito K, Park J, Akata S, Koizumi K, Tokuue K, et al. Tumoricidal effect of strontium-89. Clin Nucl Med. 2011;36:296-9.
13. Tu SM, Lin SH, Podoloff DA, Logothetis CJ. Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clin Adv Hematol Oncol. 2010;8:341-51.
14. Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care. 2012;6:310-5.